Objective: Pervious RT-PCR results revealed the possibility of effective regulation channel of Xiaoyao San in treating rats of syndrome of liver invading the spleen. This experiment was designed to explore CIS rats’ immunohistochemistry findings in hippocampal subregion CA1 and amygdaloid subregion BLA after suppressing both amygdaloid AMPA receptors by microinjection of CNQX. To compare Xiaoyao San group with CNQX group, and to analysis of these findings may prove the possibility of effective regulation channel of Xiaoyao san treating this syndrome. Methods: 75 male SD rats were randomly divided into 5 equal groups: normal group, CIS group, sham-operation group, CNQX group and Xiaoyao San group. The number of GluR2 positive cells in hippocampal subregion CA1 and amygdaloid subregion BLA in these 5 groups were examined by immunohistochemistry test. Results: Compared with control group, the number of GluR2 positive cells decreased in hippocampal subregion CA1. Statistical analysis showed that no difference existed in control, CNQX and Xiaoyao San groups in CA1 region. Except CNQX group, tendency of changes were contradictory in BLA and CA1 region. In addition, the least in BLA in CNQX group. This finding revealed that Xiaoyao San may act the same as CNQX, thus Xiaoyao San afforded effective protection against this depression syndrome through suppression of both amygdaloid excitability. Conclusion: The balance coordination between hippocampus and amygdala may be the key in transformation from adaption to damage in a state of stress, was one of the central mechanisms of liver governing smoothing qi flow (LGSQF) on regulating the stress. Xiaoyao San may effectively regulate the balance of the excitability of hippocampus and amygdala. This hypothesis may reveal the regulation channel on Xiaoyao San affording effective protection against liver invading the spleen syndrome.

Adenocarcinoma, Follicular ; classification ; metabolism ; pathology ; Adenoma ; metabolism ; pathology ; Biomarkers, Tumor ; metabolism ; Carcinoma, Papillary ; metabolism ; pathology ; Diagnosis, Differential ; Humans ; Signal Transduction ; Thyroid Neoplasms ; classification ; metabolism ; pathology

Objective To analyze the status quo and countermeasures of the development of Guangxi's private hospitals during the ongoing healthcare reform. Methods With the background of the healthcare reform, the current situation of private hospitals was analyzed based on data changes of the development of such hospitals in Guangxi during the 2011 -2015 period, for the purpose of proposing measures such as multiple supervision mechanism. Results During this period,74 private hospitals were founded in Guangxi. They have added 7 395 hospitals beds, served 1.41 million outpatient/emergency visits, and 220. 9 thousand inpatients, with 5 939 employees hired in the meantime. Given these achievements,development of these hospitals tended to be imbalanced and poorly regulated.Conclusions The healthcare reform has encouraged private involvement in medical practice and the growth of private hospitals in the region. In view of the problems as mentioned above, multiple supervision appears an effective solution.

Objective To study the changes of plasma cystatin C level (PcyC),and evaluate the effects of the joint use of atorvastatin and probucol on PcyC and severity of coronary lesion in patients with borderline lesion of coronary artery.Methods One hundred and thirty consecutive patients with borderline coronary lesion assessed by quantitative coronary angiography were enrolled into borderline coronary lesion group (BCL),and another 136 subjects without coronary lesion were enrolled as controls (CTR).And in the meantime,the subjects in BCL group were randomized (closed envelope method) into routine treatment subgroup ( RTT,n =60),and combined treatment subgroup in which patients were treated with atorvastatin 20 mg plus probucol 1.0 g daily in addition to routine medication ( CBT,n =70) for 6 months.There were no statistical differences in basic clinical features between two subgroups.PcyC,high-sensitive C-reactive protein (hs-CRP),total cholesterol (TC),low-density lipoprotein cholesterol (LDL-C),high-density lipoprotein cholesterol ( HDL-C ) and triglycerides (TG) were determined.Of them,104 patients in BCL group rechecked by coronary angiography.Comparison of biomarkers carried out between two groups by using a number of independent-sample t-test and analysis of variance.For enumeration data,chi-square test was used to compare mean values of biomarkers between groups. P ＜ 0.05 was considered statistically significant.Results PcyC levels were significantly higher in BCL group than those in CTR group ( P ＜ 0.05 ).Compared with RTT subgroup,levels of PcyC,TC,LDL-C,TG and hs-CRP were more significantly decreased in CBT subgroup (P ＜ 0.05,P ＜ 0.01 ).Moreover,there was a trend of slight decrease in the mean percent of stenosis (MPS) of coronary artery with borderline lesion in RTT subgroup treated for 6 months,whereas more marked decrease in the MPS of coronary artery with borderline coronary lesion in CBT subgroup treated for 6 months ( P ＞ 0.05 ; P ＜ 0.05 ).Conclusions Cystatin C plays an important role in the pathogenesis of coronary artery,and PcyC is associated with severity of coronary lesion,the combination of atorvastatin and probucol decreases the PcyC level,and it may be the treatment of choice for borderline lesion of coronary artery.

Objective To observe the effect of Interferon-α2b on HEL cells (human erythroleukemia cell line) growth, apoptosis and JAK2 V617F mutation gene expression. Methods HEL cells were placed in RPMI1640 containing 10% FBS and incubated in a cell incubator. Cells in the logarithmic growth phasem were collected, adjusting the cell density to 1 × 105/mL for experimental research. The interferon concentration in five groups were 0, 5 × 105, 10 × 105, 50 × 105, 100 × 105 U/L, with different incubation time (0, 24, 72, 120 h), respectively. The cell growth status in different groups was observed in the inverted optical microscope; MTT was used to detect the inhibition of interferon on HEL cell proliferation. Cell apoptosis was detected by flow cytometry. Fluorescence quantitative PCR was used to detect the mutation gene of JAK2 V617F expression. Results Inhibition rates of Interferon on the HEL cell proliferation in 5 × 105 U/L, 10 × 105 U/L, 50 × 105 U/L, 100 × 105 U/L groups were 18.57%, 25.10%, 42.10%, 57.00%, respectively. JAK2 V617F/GAPDH by fluorescence quantitative was 1.556, 1.213, 0.870 respectively under the concentration of interferon 100 × 105 U/L for 24, 72, 120 h. Conclusions Interferon-α2b can inhibit HEL cells proliferation and induce HEL cells apoptosis. Increasing concentration of interferon increases HEL cell apoptosis rate. Interferon can inhibit JAK2 V617F expression of HEL cells in a dose-dependent manner.

Objective To study the relationship between serum UA level and early outcome in acute ischemic stroke (AIS) patients. Methods Four hundred and twenty-one AIS patients admitted to the First Affiliated Hospital of Xi'an Jiaotong University from March 2015 to March 2016 were divided into good outcome group (n = 232) and poor outcome group (n = 189) according to their modified Rankin scale (mRS) score. Their demographic data, risk factors for vascular disease, laboratory testing parameters, imaging and clinical data and NIHSS score were recorded and compared. The relationship between serum UA level and early poor outcome in AIS patients was analyzed by unconditioned logistic regression analysis. Results The incidence of AF and cerebral infarction in the territory of anterior cerebral artey and middle cerebral artery, SBP, serum TC,LDL and urea levels,NIHSS and mRS score, and mortality were significantly higher and the hospital stay time was significantly longer while the serum UA level and GCS score were significantly lower in poor outcome group than in good outcome group (P＜0.05,P＜0.01). Unconditioned logistic regression analysis showed that SBP,NIHSS score and serum UA level were the major risk factors for the early poor outcome in AIS patients (OR = l.017,95％CI:1.003-1.031,P = 0.018;OR = 1.274,95％CI:1.178-1.378,P=0.000;OR=0.993,95％CI:0.989-0.996, P = 0.000). Conclusion The low serum UA level is related with the early poor outcome in AIS patients.

OBJECTIVETo investigate the incidence of JAK2V617F gene point mutation in patients with myeloproliferatives diseases (MPD) and its clinical significance.

METHODSGenomic DNA from bone marrow and peripheral blood cells were extracted from 68 patients with MPD. Allele specific polymerase chain reaction was used to amplify the exon 12 of JAK2 gene which harbours V617F mutation. The PCR products were identified by DNA sequencing. JAK2V617F gene point mutation and its impact on peripheral blood cells were analyzed.

RESULTSThe incidence of JAK2V617F mutation in 68 patients with MPD was 65.28 %. The positive rate of JAK2V617F point mutation was 77.77 % in patients with PV (36/59), 56.52 % in patients with ET (23/59) and 44.44 % in patients with IMF (4/9). In all groups, the incidence of JAK2V617F point mutation in bone marrow and peripheral blood were equal. Patients with JAK2V617F mutation in PV group had higher counts of white blood cell and hemoglobin in peripheral blood than patients without JAK2V617F point mutation (P <0.05). Patients with JAK2V617F mutation in ET group had higher counts of white blood cell than those without JAK2V617F mutation (P <0.05); there was no significant difference in platelet count.

CONCLUSIONJAK2V617F point mutation can affect the hematologic features, which may be of diagnostic value for MDP with negative BCR-ABL gene.

Adolescent ; Adult ; Aged ; Amino Acid Substitution ; Base Sequence ; Female ; Humans ; Janus Kinase 2 ; genetics ; Male ; Middle Aged ; Molecular Sequence Data ; Myeloproliferative Disorders ; enzymology ; genetics ; Point Mutation ; Young Adult

Objective To explore and analyze the prescription patterns of Professor Zhou Min in treating primary liver cancer at different stages according to the China Liver Cancer Staging (CNLC) system. Methods The clinical records of outpatients with primary liver cancer treated by Professor Zhou Min were collected and entered into the Traditional Chinese Medicine Inheritance Support System (Version 2.50) to establish a database. Data mining methods such as frequency analysis, drug association analysis, and cluster analysis were employed, the pathogenesis of primary liver cancer the prescription patterns at different stages was explored and medication rules were analyzed according to Professor Zhou Min's experience in treating liver cancer at various CNLC stages. Results A total of 202 prescriptions from 113 patients with primary liver cancer were collected, involving 230 traditional Chinese medicines. The high-frequency drugs and drug combinations at each stage were identified. The drugs with higher frequencies at each stage included Fuling, Chenpi, Yiyiren, fried Baishu, and Fabanxia. For stage Ⅰ, high-frequency drugs also included Zhongjiefeng, Xiangfu, Jiangcan, and Jianghuang. For stages Ⅱ and Ⅲ, high-frequency drugs further encompassed Zhongjiefeng, Xianhecao, Banzhilian, Baihua Sheshecao, Jiangcan, Zeqi, Xiangfu, and Maidong. For stage Ⅳ, high-frequency drugs also include Maydis stigma, Huoxiang, fried Maiya, Jineijin, and fried Guya. The majority of the drugs were cold in nature, with sweet and bitter tastes being the most common, and their meridian tropism were mostly distributed in the spleen and stomach meridians. The drug combinations with higher frequencies at each stage were mostly derived from Sijunzi Decoction and Erchen Decoction. The drug efficacies were mainly heat-clearing and dampness-resolving. Cluster analysis screened out new prescriptions with unique characteristics at each stage. Conclusion By performing data mining on the prescriptions used by Professor Zhou Min in treating primary liver cancer at various CNLC stages through the Traditional Chinese Medicine Inheritance Platform, combined with his understanding of the pathogenesis and clinical experience of the disease, the pathogenesis characteristics of primary liver cancer are summarized as dampness-heat, phlegm, and toxin accumulation, as well as qi and yin deficiency. The basic treatment methods established are heat-clearing and dampness-resolving, spleen-invigorating and yin-nourishing, with an emphasis on strengthening the body resistance to eliminate pathogenic factors and stage-based treatment. Flexible prescriptions and medications are used for different complications.

Objective To explore and analyze the prescription patterns of Professor Zhou Min in treating primary liver cancer at different stages according to the China Liver Cancer Staging (CNLC) system. Methods The clinical records of outpatients with primary liver cancer treated by Professor Zhou Min were collected and entered into the Traditional Chinese Medicine Inheritance Support System (Version 2.50) to establish a database. Data mining methods such as frequency analysis, drug association analysis, and cluster analysis were employed, the pathogenesis of primary liver cancer the prescription patterns at different stages was explored and medication rules were analyzed according to Professor Zhou Min's experience in treating liver cancer at various CNLC stages. Results A total of 202 prescriptions from 113 patients with primary liver cancer were collected, involving 230 traditional Chinese medicines. The high-frequency drugs and drug combinations at each stage were identified. The drugs with higher frequencies at each stage included Fuling, Chenpi, Yiyiren, fried Baishu, and Fabanxia. For stage Ⅰ, high-frequency drugs also included Zhongjiefeng, Xiangfu, Jiangcan, and Jianghuang. For stages Ⅱ and Ⅲ, high-frequency drugs further encompassed Zhongjiefeng, Xianhecao, Banzhilian, Baihua Sheshecao, Jiangcan, Zeqi, Xiangfu, and Maidong. For stage Ⅳ, high-frequency drugs also include Maydis stigma, Huoxiang, fried Maiya, Jineijin, and fried Guya. The majority of the drugs were cold in nature, with sweet and bitter tastes being the most common, and their meridian tropism were mostly distributed in the spleen and stomach meridians. The drug combinations with higher frequencies at each stage were mostly derived from Sijunzi Decoction and Erchen Decoction. The drug efficacies were mainly heat-clearing and dampness-resolving. Cluster analysis screened out new prescriptions with unique characteristics at each stage. Conclusion By performing data mining on the prescriptions used by Professor Zhou Min in treating primary liver cancer at various CNLC stages through the Traditional Chinese Medicine Inheritance Platform, combined with his understanding of the pathogenesis and clinical experience of the disease, the pathogenesis characteristics of primary liver cancer are summarized as dampness-heat, phlegm, and toxin accumulation, as well as qi and yin deficiency. The basic treatment methods established are heat-clearing and dampness-resolving, spleen-invigorating and yin-nourishing, with an emphasis on strengthening the body resistance to eliminate pathogenic factors and stage-based treatment. Flexible prescriptions and medications are used for different complications.